Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMT-EA Regimen for Newly Diagnosed PCNSL
NCT06946407Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, thiotepa, etoposide and cytarabine in primary central nervous system lymphoma (PCNSL). Primary endpoint: Objective Response Rate at 8 months. Started Dec 2022; status: recruiting.
02
Drugs
rituximabmethotrexatethiotepaetoposidecytarabine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06946407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946407.